Cell Reprogramming with siRNA
TRANSCRIPTIONAL DAMAGE
Many complex and age-related diseases exhibit widespread transcriptional dysregulation.
However, most drug discovery only targets a single dysregulated gene.
BREAKTHROUGH SCIENCE
Junevity founders were the first to show that repression of a single transcription factor can reprogram gene expression to a healthy state in a human cell model of aging.
Single-target siRNA reprogramming can reverse complex disease with a safe, proven modality.
JUNEVITY RESET PLATFORM
RESET is the first siRNA cell reprogramming platform, leveraging human omics data, genetic linkages, machine learning, and siRNA.
This approach offers a path to safe therapeutics with genetic evidence to reset the health of our tissues, one disease at a time.
Learn more here.
THERAPEUTICS DEVELOPMENT
Junevity is pioneering siRNA therapeutics, starting in metabolic disease and neurodegeneration. See our pipeline here.
We imagine a world with longer, healthier lives for all, powered by cell reprogramming.